3.44 USD
▼-0.10-2.69%
盘后 3.49 0.00%
2026-11-20
市值
$97.77M
市盈率
—
EPS
-1.44
股息率
—
52 周区间
3.33 – 8.74
成交量
982.18K
Beta
1.86
目标价
26.30
52W 低 3.3352W 高 8.74
价格走势
公司简介
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj...